Study shows 177Lu-PSMA-617 is noninferior to cabazitaxel in post-chemo mCRPC
Data from the phase 2 TheraP trial showed that 177Lu-PSMA-617 induced comparable overall survival outcomes as cabazitaxel in patients with metastatic castration-resistant prostate cancer who progressed after receiving docetaxel.
Focal therapy associated with improved QOL in non-metastatic prostate cancer
Investigators analyzed data from over 1300 patients undergoing treatment for prostate cancer at 5 hospitals.
2 Clarke Drive Cranbury, NJ 08512